|
|
|
Insider
Information: |
Kania Edwin M Jr |
Relationship: |
10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
19 |
|
Direct
Shares |
11,446,567 |
|
Indirect Shares
|
62,961,806 |
|
|
Direct
Value |
$115,556,491 |
|
|
Indirect Value
|
$160,922,477 |
|
|
Total
Shares |
74,408,373 |
|
|
Total
Value |
$276,478,968 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
Percentage
Gain/Loss : |
115.9%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Exact Sciences Corp |
EXAS |
Director |
2009-07-20 |
172,503 |
2009-07-20 |
1,202,787 |
Premium* |
|
Tetraphase Pharmaceuticals Inc |
TTPH |
10% Owner |
2013-03-25 |
1,165,786 |
2013-03-25 |
0 |
Premium* |
|
Acceleron Pharma Inc |
XLRN |
Director |
2014-12-23 |
28,734 |
2014-12-23 |
544,055 |
Premium* |
|
DNIB Upwind Inc |
BIND |
10% Owner |
2013-09-25 |
0 |
2013-09-25 |
1,562,616 |
Premium* |
|
Carisma Therapeutics Inc |
CARM |
10% Owner |
2016-09-23 |
1,940,589 |
|
0 |
Premium* |
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2014-02-19 |
656,490 |
|
0 |
Premium* |
|
T2 Biosystems, Inc. |
TTOO |
10% Owner |
2014-08-12 |
0 |
2014-08-12 |
2,374,571 |
Premium* |
|
Bg Medicine, Inc. |
BGMD |
10% Owner |
2014-12-04 |
0 |
2014-12-11 |
4,915,402 |
Premium* |
|
Seres Therapeutics, Inc. |
MCRB |
10% Owner |
|
0 |
2016-05-25 |
0 |
Premium* |
|
Selecta Biosciences Inc |
SELB |
Director |
2017-05-16 |
26,528 |
2017-05-16 |
560,067 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
10% Owner |
2017-08-17 |
2,378,663 |
2017-08-17 |
262,386 |
Premium* |
|
Editas Medicine, Inc. |
EDIT |
10% Owner |
2016-08-11 |
2,764,256 |
2016-08-11 |
45,422 |
Premium* |
|
Quanterix Corp |
QTRX |
10% Owner |
2017-12-11 |
2,030,495 |
2017-12-11 |
0 |
Premium* |
|
Evelo Biosciences Inc |
EVLO |
10% Owner |
2018-05-11 |
0 |
2018-05-11 |
18,233,403 |
Premium* |
|
Rubius Therapeutics, Inc. |
RUBY |
10% Owner |
2018-07-20 |
0 |
2018-07-20 |
7,563,703 |
Premium* |
|
Moderna, Inc. |
MRNA |
10% Owner |
2020-01-14 |
23,847 |
2019-12-11 |
20,253,972 |
Premium* |
|
Kaleido Biosciences, Inc. |
KLDO |
10% Owner |
|
0 |
2019-03-04 |
2,682,840 |
Premium* |
|
Transmedics Group, Inc. |
TMDX |
|
2024-05-23 |
258,676 |
2024-05-23 |
46,142 |
Premium* |
|
Axcella Health Inc. |
AXLA |
10% Owner |
|
0 |
2019-05-08 |
2,714,440 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
EXAS |
Exact Sciences Corp |
Director |
|
2005-10-26 |
4 |
A |
$2.08 |
$9,999 |
D/D |
4,807 |
82,036 |
|
- |
|
EXAS |
Exact Sciences Corp |
Director |
|
2006-07-21 |
4 |
A |
$2.09 |
$9,999 |
D/D |
4,784 |
86,820 |
|
- |
|
EXAS |
Exact Sciences Corp |
Director |
|
2007-08-10 |
4 |
A |
$3.00 |
$30,000 |
D/D |
10,000 |
96,820 |
0 |
- |
|
EXAS |
Exact Sciences Corp |
Director |
|
2008-07-18 |
4 |
A |
$0.71 |
$7,100 |
D/D |
10,000 |
106,820 |
0 |
- |
|
EXAS |
Exact Sciences Corp |
Director |
|
2009-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,344 |
167,164 |
0 |
- |
|
EXAS |
Exact Sciences Corp |
Director |
|
2009-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,339 |
172,503 |
0 |
- |
|
TTPH |
Tetraphase Pharmaceutical... |
10% Owner |
|
2013-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,565,849 |
673,962 |
0 |
- |
|
TTPH |
Tetraphase Pharmaceutical... |
10% Owner |
|
2013-03-25 |
4 |
B |
$7.00 |
$3,442,768 |
D/D |
491,824 |
1,165,786 |
2.45 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2013-09-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,276,479 |
2,281,346 |
0 |
- |
|
BIND |
DNIB Upwind Inc |
10% Owner |
|
2013-09-25 |
4 |
B |
$15.00 |
$300,000 |
I/I |
20,000 |
1,562,616 |
1.5 |
- |
|
BIND |
DNIB Upwind Inc |
10% Owner |
|
2013-09-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,542,616 |
1,542,616 |
0 |
- |
|
CARM |
Carisma Therapeutics Inc |
10% Owner |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,574,844 |
260,356 |
0 |
- |
|
CARM |
Carisma Therapeutics Inc |
10% Owner |
|
2014-02-11 |
4 |
B |
$10.00 |
$3,787,290 |
D/D |
378,729 |
293,268 |
2.45 |
- |
|
CNCE |
Concert Pharmaceuticals, ... |
10% Owner |
|
2014-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
623,982 |
656,490 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2014-04-22 |
4 |
AS |
$35.89 |
$4,367,167 |
I/I |
(121,682) |
122,823 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2014-04-23 |
4 |
AS |
$33.81 |
$801,297 |
I/I |
(23,700) |
121,472 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2014-04-24 |
4 |
AS |
$31.45 |
$26,877,736 |
I/I |
(854,618) |
72,759 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2014-05-05 |
4 |
S |
$42.86 |
$9,220,986 |
I/I |
(215,142) |
60,496 |
0 |
- |
|
TTOO |
T2 Biosystems, Inc. |
10% Owner |
|
2014-08-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,374,571 |
2,374,571 |
0 |
- |
|
BGMD |
Bg Medicine, Inc. |
10% Owner |
|
2014-12-04 |
4 |
A |
$0.00 |
$0 |
I/I |
634,390 |
604,149 |
0 |
- |
|
BGMD |
Bg Medicine, Inc. |
10% Owner |
|
2014-12-09 |
4 |
S |
$0.36 |
$47,552 |
I/I |
(132,090) |
478,360 |
0 |
- |
|
BGMD |
Bg Medicine, Inc. |
10% Owner |
|
2014-12-10 |
4 |
S |
$0.32 |
$36,710 |
I/I |
(114,720) |
369,112 |
0 |
- |
|
BGMD |
Bg Medicine, Inc. |
10% Owner |
|
2014-12-11 |
4 |
S |
$0.30 |
$116,274 |
I/I |
(387,580) |
0 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2014-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
23,867 |
28,734 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
Director |
|
2014-12-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(597,920) |
251 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|